



Press Release

Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma's Cell Culture Based Influenza Vaccine Programs in Japan

Tokyo and Akita, Japan, September 30, 2010 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and UMN Pharma Inc. ("UMN Pharma"; headquarters: Akita, President & CEO: Shu-Ichi Kanazashi) announced today that the both companies entered into the definitive agreement for UMN-0501 and UMN-0502 (the "Licensed Programs"), which are cell culture based influenza vaccine programs developed by UMN Pharma, on September 21, 2010. Under the agreement, the both companies will co-develop the Licensed Programs and Astellas will exclusively commercialize them in Japan. The execution of a memorandum of understandings as of August 16, 2010 was already announced on August 17, 2010.

【Outline of definitive agreement】

- Astellas is granted co-development and exclusive commercialization rights for the Licensed Programs in Japan
 - UMN-0501 is a cell culture based H5N1 avian influenza vaccine.
Currently, it is under preparation for Phase III clinical trial in Japan.
 - UMN-0502 is a cell culture based seasonal influenza vaccine.
Currently, it is under preparation for Phase I/II clinical trial in Japan.
- Astellas will lead the further development and bear all the costs.
- UMN Pharma is responsible for manufacturing, will supply the final commercial products to Astellas, and Astellas will be selling the commercial products.

###

Contact Information:

Astellas

Corporate Communications

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

<http://www.astellas.com/en>

UMN Pharma

Tsuyoshi Teshima

General Manager of Corporate Planning Division

Tel: +81-45-624-8341

press@umnpharma.com